- Category
- Small (2023-24)
- Udyam number
- UDYAM-HP-11-0009118

About Dallas Formulations Private Limited
Data last updated:
Dallas Formulations Private Limited is a private limited company based in Ujjain, Madhya Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 November 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U24233MP2000PTC014476. Its GSTIN is 02AACCD5000G1ZJ (Himachal Pradesh).
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹39.09 Lakh. It was formerly known as Chirayu Ayurveda Private Limited. It is led by directors Mukesh Kumar (Whole-Time Director) and Rajesh Gupta.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 220 Block – C 2nd Floor Madhav Club Road Dawa Bazar, Ujjain, Madhya Pradesh, India – 456010.
As per the financials filed for FY 2025, the company reported a revenue of ₹10.53 Cr, a growth of 47% compared to the previous year. For the same year it recorded a net profit of ₹17.31 Lakh (net margin 1.6%) and EBITDA of ₹85.56 Lakh (EBITDA margin 8.1%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 2% over five years.
The company has about 20 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Dallas Formulations. As per MCA filings, the company has open charges of ₹2.66 Cr and satisfied charges of ₹5.24 Cr on record. Court records list 9 cases involving the company, including 3 filed by the company and 6 filed against it; 1 case is pending.
Dallas Formulations Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0009118). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dallaspharma.com.
Company details
Recognitions & Rankings of Dallas Formulations
Contact details
Dallas Formulations Private Limited's registered office is in Ujjain, Madhya Pradesh. Its website is dallaspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address220 Block – C 2nd Floor Madhav Club Road Dawa Bazar, Ujjain, Madhya Pradesh, India – 456010
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dallas Formulations Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Dallas Formulations operates one associated brand: Dallas Formulations. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures pharmaceutical tablets, capsules, and injectables for health markets. | dallaspharma.com |
Business activity
The main business activity of Dallas Formulations is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Dallas Formulations Private Limited, buy the company report.
Financials of Dallas Formulations Private Limited
FY 2024 filings availableDallas Formulations Private Limited reported revenue of ₹10.53 Cr (up 47% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 2% over five years, including 47% growth in the latest year. EBITDA rose 8% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹85.56 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹17.31 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.1% | ||||
| Net Profit Margin | 1.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dallas Formulations Private Limited, buy the company report.
Board of directors of Dallas Formulations Private Limited
Dallas Formulations has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajesh Gupta Also directs: Rudraksha Entertainment LLP, Dallas Drugs Private Limited, Dauket Pharma Private Limited and 3 more | Director | 16 Jan 2006 | 20 Years 10 Months | Current |
| Mukesh Kumar | Whole-Time Director | 21 Jul 2022 | 4 Years 3 Months | Current |
Peer comparison
Dallas Formulations Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pharmtech Solutions Private Limited | ₹10.59 Cr (FY 2019) | 397.0% | Hyderabad, Telangana, India | |||
| Salus Laboratories Private Limited | ₹10.59 Cr (FY 2024) | 45.0% | Madhura Nagar, Telangana, India | |||
| Biowin Healthcare Limited | ₹10.57 Cr (FY 2025) | -3.0% | Ahmedabad, Gujarat, India | |||
| Dallas Formulations Private Limitedthis company | ₹10.53 Cr (FY 2025) | ₹17.31 Lakh | 1.6% | 47.0% | 20 | Ujjain, Madhya Pradesh, India |
| Astron Pharmaceuticals Private Limited | ₹10.49 Cr (FY 2025) | 15.0% | New Delhi, Delhi, India | |||
| Sri Mallikarjuna Chemicals Private Limited | ₹10.49 Cr (FY 2024) | 25.0% | Hyderabad, Telangana, India | |||
| Biomiicron Pharma India Private Limited | ₹10.49 Cr (FY 2024) | -1.0% | Chennai, Tamil Nadu, India | |||
| Wizcure Pharmaa Private Limited | ₹10.47 Cr (FY 2024) | 17.0% | Alwar, Rajasthan, India |
To see the full peer comparison of Dallas Formulations Private Limited, buy the company report.
Auditor
Dallas Formulations Private Limited is audited by V.K. Ladha & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| V.K. Ladha & Associates | FY 2024 | 002301C |
Shareholding
The shareholding of Dallas Formulations Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dallas Formulations Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Nov 2006 | 10030257 | State Bank of India | ₹2.66 Cr | Open | |
| 28 Nov 2013 | 10466437 | Ing Vysya Bank Limited | ₹1.75 Cr | Satisfied | |
| 17 Aug 2011 | 10302287 | Dir. of Industries with Parri Passu Sbi Baddi | ₹1.29 Cr | Satisfied | |
| 29 Apr 2006 | 10016367 | State Bank of India | ₹2.2 Cr | Satisfied |
To see the full charge records of Dallas Formulations Private Limited, buy the company report.
Total charge records: 4 View all charges
Legal cases
Dallas Formulations Private Limited has 9 court cases on record: 3 filed by Dallas Formulations, 6 filed against it. 1 case is pending and 8 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 4 | 0 |
| District courts | 3 | 1 | 1 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 9)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North Twenty Four Parganas, West Bengal | Criminal complaint | Filed against the company by West Bengal Chemical Industries Limited | Pending |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Anr. | Disposed |
| High Court | Criminal miscellaneous application | Filed against the company by an individual | Disposed |
| High Court | Criminal miscellaneous application | Filed against the company by M/S Bharat Salt and Chemicals Industries and Anr and 1 other | Disposed |
| District court, Panchkula, Haryana | Cheque dishonour complaint | Filed by the company against M/S Bharat Salt and Chemicals Ind. Limited and 4 others | Disposed |
To see the full case history of Dallas Formulations Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dallas Formulations Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Dallas Formulations Private Limited has a workforce of 20 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 20 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Dallas Formulations Private Limited, buy the company report.
GST
Dallas Formulations has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AACCD5000G1ZJ | Himachal Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Dallas Formulations Private Limited, buy the company report.
Recent activity
Dallas Formulations Private Limited has 5 board changes on record since 2006: 2 appointments and 3 cessations. The latest: Mukesh Kumar was appointed as Whole-Time Director on 21 Jul 2022.
5 earlier events are in the company report.
Frequently asked questions
Dallas Formulations is an active private limited company based in Ujjain, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 November 2000 (26+ years old) and is registered under CIN U24233MP2000PTC014476.
Dallas Formulations has 2 current directors:
- Mukesh Kumar - Whole-Time Director
- Rajesh Gupta - Director
The latest financial statements of Dallas Formulations on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Dallas Formulations is 02AACCD5000G1ZJ, registered in Himachal Pradesh.
The CIN (Corporate Identification Number) of Dallas Formulations is U24233MP2000PTC014476. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dallas Formulations has 9 court cases on record: 3 filed by the company and 6 filed against it. 1 is pending. Most are in the high courts.
Dallas Formulations was incorporated on 24 November 2000, making it 26+ years old. It is registered with the Registrar of Companies, Gwalior.
The peers of Dallas Formulations by revenue are Pharmtech Solutions Private Limited, Salus Laboratories Private Limited, Biowin Healthcare Limited, Astron Pharmaceuticals Private Limited, Sri Mallikarjuna Chemicals Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Mukesh Kumar was appointed as Whole-Time Director on 21 Jul 2022. Anil Kumar ceased to be Additional Director on 30 Sep 2019. Nandkishore Maheshwari ceased to be Director on 04 Oct 2018. Dallas Formulations has 5 board changes on record in total.
Yes, Dallas Formulations is registered as a small enterprise under Udyam registration (number: UDYAM-HP-11-0009118).
Dallas Formulations can be reached through the website dallaspharma.com. Its registered office is in Ujjain, Madhya Pradesh, India.

